Terms ending in 2030
Every in-force patent on Amgen Inc.'s record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,609,655 | Calcimimetic Compound for Use in the Treatment of Epithelial Injury In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 8,053,236 | Feed Media In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 9,228,168 | Feed Media In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 9,732,134 | Methods of Treating Graft Versus Host Disease Using IL-2 Muteins In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 11,560,415 | Method of Promoting Regulatory T-Cell Proliferation In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 12,297,248 | Methods of Treating Graft Versus Host Disease Using IL-2 Muteins In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 8,080,546 | Pyrazolo-Pyridinone Derivatives and Methods of Use In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 8,030,354 | Substituted Biphenyl GPR40 Modulators In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 8,012,767 | Pipette Tip Loading Assembly In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 9,499,620 | Methods of Using an ALPHA-4-BETA-7 Heterodimer Specific Antagonist Antibody In force · Medium confidence | Amgen Inc. | In force | Medium confidence | |
| 64 more term ends in 2030 · Pro | |||||
10 of 74 patents shown. Soonest term end first, then patent number.
Pro members see all 74.
71 of these are in force and held by Amgen Inc..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.